| Company: | Forest Laboratories, Inc. |
| Ticker Symbol: | NYSE: FRX |
| Class Period: | August 15, 2002 to September 1, 2004 |
| Date Filed: | Mar-11-05 |
| Lead Plaintiff Deadline: | May-09-05 |
| Court: | Southern District, NY |
| Allegations: |
A class action has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Forest Laboratories, Inc. ("Forest Labs") (NYSE:FRX) common stock during the period between August 15, 2002 and September 1, 2004 (the "Class Period").
The complaint charges Forest Labs and certain of its officers and directors with violations of the Securities Exchange Act of 1934. Forest Labs develops, manufactures and sells prescription drug products, as well as non-prescription pharmaceutical products.
According to the complaint, during the Class Period, defendants caused Forest Labs' stock price to be overstated by concealing deficiencies with its Celexa/Lexapro drugs in treating adolescent depression. When Forest Labs ultimately disclosed an agreement with the New York State Attorney General to make available summaries of previously undisclosed studies on the drugs to the public, the price of Forest Labs stock dropped to as low as $36 per share.
If you acquired the securities of the defendants during the Class Period you may, no later than the Lead Plaintiff Deadline shown above, request that the Court appoint you as lead plaintiff through counsel of your choice. You may also choose to remain an absent class member. A lead plaintiff must meet certain requirements.
The complaint charges Forest Labs and certain of its officers and directors with violations of the Securities Exchange Act of 1934. Forest Labs develops, manufactures and sells prescription drug products, as well as non-prescription pharmaceutical products.
According to the complaint, during the Class Period, defendants caused Forest Labs' stock price to be overstated by concealing deficiencies with its Celexa/Lexapro drugs in treating adolescent depression. When Forest Labs ultimately disclosed an agreement with the New York State Attorney General to make available summaries of previously undisclosed studies on the drugs to the public, the price of Forest Labs stock dropped to as low as $36 per share.
If you acquired the securities of the defendants during the Class Period you may, no later than the Lead Plaintiff Deadline shown above, request that the Court appoint you as lead plaintiff through counsel of your choice. You may also choose to remain an absent class member. A lead plaintiff must meet certain requirements.
If you feel you qualify for damages or remedies that might be awarded in this class action please fill in our form on the right to submit your complaint.
If you are a current or former employee of this company, and have 401(k) shares, please use this form to register your complaint. Thank you.
